Abstract
We assessed the impact on survival of angiogenesis and inflammation-related factors, particularly LDH serum levels, platelet, neutrophil and lymphocyte counts, and neutrophil-to-lymphocyte ratio (NLR), in metastatic colorectal cancer patients receiving regorafenib monotherapy. LDH serum levels, neutrophil, lymphocyte and platelet counts were collected at the start of regorafenib monotherapy. Cut-off values were calculated by ROC curve analysis. Survival analyses were performed by Kaplan-Meier method, and multivariate analysis by Cox method. A total of 208 patients were eligible for analysis. Among factors who were related with worse overall survival and who maintained their role at the multivariate analysis, high platelet count (Exp(b):1.4963, 95% CI:1.0130-2.2103, p = 0.0439) and high neutrophil/lymphocyte ratio (Exp(b):1.6963, 95% CI:1.0757-2.6751, p = 0.0237) were those who more deeply were related to worse overall survival. High lymphocyte count (Exp(b):0.4527, 95% CI:0.2801-0.7316, p = 0.0013) was correlated with improved overall survival. High neutrophil, high platelet, low lymphocyte count and/or high NLR may represent negative prognostic factors in patients receiving regorafenib monotherapy. It is advisable that these f...Continue Reading
References
May 30, 2001·Current Opinion in Genetics & Development·P H MaxwellP J Ratcliffe
Jul 28, 2001·American Journal of Clinical Oncology·F TasE Topuz
Jan 22, 2002·American Journal of Clinical Oncology·F TasE Topuz
Mar 21, 2002·Nature Reviews. Cancer·Adrian L Harris
Dec 5, 2003·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Michael I KoukourakisUNKNOWN Tumour and Angiogenesis Research Group
May 29, 2004·Angiogenesis·Yoka H KusumantoNanno H Mulder
Aug 17, 2004·Immunity·Gavin P DunnRobert D Schreiber
Aug 25, 2005·Journal of Surgical Oncology·S R WalshN J Keeling
Sep 1, 2005·Clinical & Experimental Metastasis·Michael I KoukourakisEfthimios Sivridis
Dec 13, 2005·Pancreas·Paola FogarMario Plebani
Dec 19, 2007·Pharmacogenomics·Mizutomo AzumaHeinz-Josef Lenz
Jul 25, 2008·Nature·Alberto MantovaniFrances Balkwill
Jan 9, 2009·Annals of Surgical Oncology·Yoji KishiJean-Nicolas Vauthey
May 27, 2009·Carcinogenesis·Francesco ColottaAlberto Mantovani
Aug 24, 2010·World Journal of Gastroenterology : WJG·Xiong-Zhi WuXue-Lin Wang
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Mar 31, 2011·British Journal of Cancer·W ChuaS J Clarke
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemEdward Lin
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Randolph HechtDavid Kerr
Jun 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael I KoukourakisAdrian L Harris
Jun 7, 2011·The Lancet Oncology·Richard A AdamsUNKNOWN MRC COIN Trial Investigators
Jul 5, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michael J ProctorDonald C McMillan
Feb 9, 2012·British Journal of Cancer·M ScartozziS Cascinu
Jul 26, 2012·British Journal of Cancer·M J ProctorS J Clarke
Oct 9, 2012·The Journal of Urology·Sunil SarohaTahseen Al-Saleem
Nov 28, 2012·Lancet·Axel GrotheyUNKNOWN CORRECT Study Group
Mar 19, 2013·BMC Cancer·Stephen ClarkeNiall Tebbutt
Jul 4, 2013·British Journal of Cancer·G AbsengerA Gerger
Jul 4, 2013·British Journal of Cancer·M IshizukaK Kubota
Oct 15, 2013·International Journal of Cancer. Journal International Du Cancer·Mu-Xing LiYi Lv
Jan 1, 2014·Surgical Oncology·Ashvin ParamanathanDavid Lawson Morris
Jul 16, 2014·Seminars in Oncology·Paloma Guillem-LlobatPaola Patrignani
Citations
Apr 28, 2016·Scientific Reports·Riccardo GiampieriStefano Cascinu
Apr 12, 2016·Scientific Reports·Luca FaloppiMario Scartozzi
Feb 15, 2017·Scientific Reports·Xi-Lei ZhouYu-Suo Tong
Nov 22, 2017·Oncotarget·Chong LuZhenning Wang
Jun 27, 2018·Drugs·Sohita Dhillon
Jun 21, 2018·Medicine·Gerardo RosatiDomenico Bilancia
Feb 9, 2019·Scientific Reports·Chin KuoMu-Hung Tsai
Apr 3, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·C PedrazzaniA Guglielmi
Apr 19, 2017·Oncotarget·Randy C BowenHung T Khong
Feb 17, 2017·Therapeutic Advances in Medical Oncology·Rachel Riechelmann, Axel Grothey
Dec 7, 2017·ESMO Open·Erika MartinelliTeresa Troiani
Sep 20, 2017·British Journal of Cancer·Riccardo GiampieriMario Scartozzi
Sep 29, 2017·International Journal of Clinical Oncology·Chiara BaratelliGiorgio Vittorio Scagliotti
Feb 17, 2019·Cancers·Maria Silvia ConaMassimo Di Nicola
Mar 14, 2020·BMC Cancer·Li-Jian XiaHui Yang
Jun 18, 2016·BioMed Research International·Luca FaloppiMario Scartozzi
Nov 12, 2016·Oncotarget·Yu LongChengya Zhou
Apr 6, 2017·Scientific Reports·Riccardo GiampieriMario Scartozzi
Mar 24, 2018·Future Oncology·Christelle de la Fouchardière
Aug 10, 2017·Gut·Khurum KhanNicola Valeri
Nov 24, 2020·Therapeutic Advances in Medical Oncology·Min-Sang LeeSeung Tae Kim
Apr 12, 2021·International Journal of Clinical Oncology·Daichi WatanabeAkio Suzuki
Apr 22, 2021·Journal of Gastrointestinal Cancer·Atike Pınar ErdoğanAhmet Dirican
Aug 26, 2021·Clinical Colorectal Cancer·Eleonora LaiUNKNOWN GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente, Italian Group for the Study of Gastrointestinal